FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560350108> ?p ?o ?g. }

• W2560350108 abstract "Abstract Introduction: Despite the advances observed in the outcome of pediatric acute lymphoblastic leukemia (ALL) treatment during the last 20 years, relapse remains the most common cause of treatment failure in childhood ALL. Several factors have been associated to the prognosis of these patients; however, minimal residual disease (MRD) emerges as a relevant predictor of outcome. Objectives: The aims of this study were to assess MRD by flow-cytometry in relapsed ALL and to evaluate its prognostic impact as a predictor factor of outcome at the end of the induction therapy and prior to hematopoietic stem cell transplantation (HSCT). Patients and Methods: From Aug'10 to Jun'15, 123 ALL patients were treated at our center. MRD determination at least at two time-points during relapse treatment was a requirement for considering a patient eligible for the present study. Sixty-six cases were excluded due to the following causes: 10 patients died during induction, 2 died early in complete remission (CR), 29 did not respond to chemotherapy, in 13 patients MRD determination was not performed: 4 did not have clinical data available, 4 patients were Down Syndrome and 4 children received treatment for relapse in other centers. Thus, fifty-seven patients achieved CR and were evaluated for MRD at two time points. Of them, 56 patients belonged to S4 and S3 and 1 patient to S1 group as defined by the Berlin-Frankfurt-Münster stratification for relapsed ALL. MRD was analyzed by multiparametric flow-cytometry following ALL-IC 2009 guidelines. Negative MRD was defined as disclosing less than 0.1% of blasts. For this analysis, patients were stratified based on MRD levels at two different time points: after end of induction, before HSCT or at any other time point during the follow-up for patients who did not undergo HSCT. Three groups were defined: Group-1: negative at both time points (n= 23), Group-2: positive at 1 time point (n= 13) and Group-3: positive at both time points (n= 21). Patients who relapsed before receiving HSCT were considered Group-3. Twenty-five patients underwent HSCT: 13 of them from Group-1, 9 from Group-2 (2 had positive MRD previous to receive HSCT) and 3 patients from Group-3. HSCT was performed with matched familiar donor in 16 cases and matched unrelated donor in 9 cases. Results: The distribution of events according to receiving or not HSCT was: 5 died due to transplant related mortality (TRM), 9 relapsed after receiving HSCT and 16 during treatment with chemotherapy. With a median follow-up of 16 (range: 6-67) months, overall 3-year EFS probability (EFSp) (SE) was 32 (8)%. The 3-year EFSp was 75 (11)% for Group-1, 24 (14)% for Group-2 and 0% for Group-3 (p-value <0.00001). Comparing patients who did not receive HSCT vs. patients who did, EFSp (SE) was 32 (12)% and 29 (11)% respectively (p-value: non-significant). The EFSp (SE) according to MRD groups in patients who underwent HSCT was: Group-1: 53 (19)%, Group-2: 14 (13)% and 0% for Group-3 (p-value: 0.06). Conclusions: MRD quantification by flow-cytometry demonstrated to be a significant prognostic factor for relapsed ALL. Both, TRM and death in CR rates, were high and should be decreased by improving supportive measures. MRD determination by flow-cytometry in patients who underwent HSCT showed a trend to achieve a better EFSp, thus representing a relevant tool for stratifying relapsed ALL patients in order to achieve a better selection of patients to receive HSCT. Disclosures No relevant conflicts of interest to declare." @default.
• W2560350108 created "2016-12-16" @default.
• W2560350108 creator A5000934168 @default.
• W2560350108 creator A5001380475 @default.
• W2560350108 creator A5010238699 @default.
• W2560350108 creator A5012423027 @default.
• W2560350108 creator A5015975187 @default.
• W2560350108 creator A5038636514 @default.
• W2560350108 creator A5044891322 @default.
• W2560350108 creator A5054576013 @default.
• W2560350108 creator A5075571330 @default.
• W2560350108 creator A5079587139 @default.
• W2560350108 creator A5087034794 @default.
• W2560350108 creator A5088346031 @default.
• W2560350108 date "2015-12-03" @default.
• W2560350108 modified "2023-09-27" @default.
• W2560350108 title "Predictive Value of Minimal Residual Disease: Analysis By Flow-Cytometry in Children with Relapsed Acute Lymphoblastic Leukemia" @default.
• W2560350108 doi "https://doi.org/10.1182/blood.v126.23.2494.2494" @default.
• W2560350108 hasPublicationYear "2015" @default.
• W2560350108 type Work @default.
• W2560350108 sameAs 2560350108 @default.
• W2560350108 citedByCount "0" @default.
• W2560350108 crossrefType "journal-article" @default.
• W2560350108 hasAuthorship W2560350108A5000934168 @default.
• W2560350108 hasAuthorship W2560350108A5001380475 @default.
• W2560350108 hasAuthorship W2560350108A5010238699 @default.
• W2560350108 hasAuthorship W2560350108A5012423027 @default.
• W2560350108 hasAuthorship W2560350108A5015975187 @default.
• W2560350108 hasAuthorship W2560350108A5038636514 @default.
• W2560350108 hasAuthorship W2560350108A5044891322 @default.
• W2560350108 hasAuthorship W2560350108A5054576013 @default.
• W2560350108 hasAuthorship W2560350108A5075571330 @default.
• W2560350108 hasAuthorship W2560350108A5079587139 @default.
• W2560350108 hasAuthorship W2560350108A5087034794 @default.
• W2560350108 hasAuthorship W2560350108A5088346031 @default.
• W2560350108 hasConcept C126322002 @default.
• W2560350108 hasConcept C143998085 @default.
• W2560350108 hasConcept C187212893 @default.
• W2560350108 hasConcept C2777408962 @default.
• W2560350108 hasConcept C2778461978 @default.
• W2560350108 hasConcept C2779823535 @default.
• W2560350108 hasConcept C2780073493 @default.
• W2560350108 hasConcept C2909962599 @default.
• W2560350108 hasConcept C2911091166 @default.
• W2560350108 hasConcept C71924100 @default.
• W2560350108 hasConceptScore W2560350108C126322002 @default.
• W2560350108 hasConceptScore W2560350108C143998085 @default.
• W2560350108 hasConceptScore W2560350108C187212893 @default.
• W2560350108 hasConceptScore W2560350108C2777408962 @default.
• W2560350108 hasConceptScore W2560350108C2778461978 @default.
• W2560350108 hasConceptScore W2560350108C2779823535 @default.
• W2560350108 hasConceptScore W2560350108C2780073493 @default.
• W2560350108 hasConceptScore W2560350108C2909962599 @default.
• W2560350108 hasConceptScore W2560350108C2911091166 @default.
• W2560350108 hasConceptScore W2560350108C71924100 @default.
• W2560350108 hasLocation W25603501081 @default.
• W2560350108 hasOpenAccess W2560350108 @default.
• W2560350108 hasPrimaryLocation W25603501081 @default.
• W2560350108 hasRelatedWork W1515379638 @default.
• W2560350108 hasRelatedWork W2397849405 @default.
• W2560350108 hasRelatedWork W2417044364 @default.
• W2560350108 hasRelatedWork W2523114003 @default.
• W2560350108 hasRelatedWork W2537976142 @default.
• W2560350108 hasRelatedWork W2547475630 @default.
• W2560350108 hasRelatedWork W2558285505 @default.
• W2560350108 hasRelatedWork W2565788257 @default.
• W2560350108 hasRelatedWork W2569759426 @default.
• W2560350108 hasRelatedWork W2587128734 @default.
• W2560350108 hasRelatedWork W2588485349 @default.
• W2560350108 hasRelatedWork W2588619253 @default.
• W2560350108 hasRelatedWork W2923077390 @default.
• W2560350108 hasRelatedWork W2946959416 @default.
• W2560350108 hasRelatedWork W2979770315 @default.
• W2560350108 hasRelatedWork W2980703156 @default.
• W2560350108 hasRelatedWork W2986933360 @default.
• W2560350108 hasRelatedWork W3093109425 @default.
• W2560350108 hasRelatedWork W3126200053 @default.
• W2560350108 hasRelatedWork W643910028 @default.
• W2560350108 isParatext "false" @default.
• W2560350108 isRetracted "false" @default.
• W2560350108 magId "2560350108" @default.
• W2560350108 workType "article" @default.